NEW YORK (GenomeWeb News) — Epigenomics today said second-quarter revenue fell 17 percent as R&D spending rose 17 percent and net loss decreased 21 percent.
 
Total receipts for the three months ended June 30 fell to €524,000 ($718,000) from €628,000 year over year.
 
The company said €511,000 of its €1.3 million total half-year revenue came from residuals from a collaboration with Roche Diagnostics, which officially ended in March.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.